Vivos Inc (RDGL)

[Paulie Pennies]

UNFORTUNATELY YOU ARE RIGHT THE 4 MAJOR PROBLEMS THE COMPANY HAS NOT ADDRESSED

Richland, WA, May 01, 2018 (GLOBE NEWSWIRE)

1. Five cats were treated at Washington State University over the course of 15 months for feline sarcoma.

The final report is near completion and the results will be presented at the Annual Meeting of the Society of Nuclear Medicine and Medical Imaging (SNMMI), June 23-26, 2018, Philadelphia, Pennsylvania.

WHY HAS THE COMPANY REFUSED TO PUBLICLY RELEASE THIS REPORT

2. George Sharp has Publicly Stated He Owns 7 Million Shares of RDGL



YET NO ONE KNOWS THE STATUS OF THESE SHARES SILENCE FROM THE COMPANY

3. CONTRACT WITH UNIVERSITY OF MISSOURI EXPIRED WEDNESDAY AT MIDNIGHT

Pursuant to the terms of the contract with the University of Missouri, it will be responsible for conducting studies regarding in vivo dosimetry and toxicity of intralesional Y-90 phosphate nanoparticles for the treatment of soft tissue carcinoma and equine sarcoids. The term of the contract is November 1, 2017 through October 31, 2018.

https://www.otcmarkets.com/filing/html?id=12530010&guid=KCZMUpULUxw8ith

4. CONTRACT WITH BATTELLE FOR HUMAN USE EXPIRED OCTOBER 31, 2018

On or before the last day of October 2018, LICENSEE shall conclude human trials



Section 10.29 https://www.otcmarkets.com/filing/html?id=12530010&guid=KCZMUpULUxw8ith